Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUTOMAIN: Hydroxychloroquine and Nelfinavir Maintenance in Ovarian Cancer
NCT06971744Phase 2Recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine and nelfinavir in ovarian cancer, sponsored by Medical University of South Carolina. Primary endpoints: Safety of combination of study drugs at 6 months and Evaluation of Anti Tumor Activity at 6 months. Started Dec 2025; status: recruiting.
02
Drugs
hydroxychloroquinenelfinavir
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06971744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06971744.